Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No Orkambi Deal Yet For England, But Vertex’ Portfolio Approach Still On The Table

Executive Summary

Dialogue between Vertex and NHS England over cystic fibrosis drug Orkambi are set to continue after productive talks on April 25.

You may also be interested in...

NHS England Offers Vertex Final Orkambi Deal

The increasingly public row between Vertex and NHS England continues as NHS England claims it has offered Vertex the “largest ever financial commitment of its type” in its 70-year history. Meanwhile, Vertex has revealed that the NHS has offered a price that is significantly lower than the list price.

Vertex/NHS England Orkambi Talks Plod On

Talks between NHS England and Vertex over cystic fibrosis drug Orkambi are yet to bear fruit, but further discussions could take place next week.

Vertex And NHS England To Do 'More Talking’ This Week On Reimbursing Orkambi

Vertex Pharmaceuticals and NHS England are due to meet this week to see whether they can resolve their pricing deadlock over the cystic fibrosis drug Orkambi. Meanwhile, UK ministers are urging the company to bring these negotiations to an urgent resolution.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts